

## **Bruce E. Johnson, MD**

Bruce E. Johnson, MD is Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School and Brigham and Women's Hospital. He is the leader of the Dana-Farber/Harvard Cancer Center Lung Cancer Program and the Principal Investigator of the Dana-Farber/Harvard Cancer Center Specialized Program of Research Excellence (SPORE) in Lung Cancer.

Dr. Johnson's research showed patients with small cell lung cancer could be cured with chemotherapy plus chest radiotherapy and documented the long-term sequelae and second malignancies. His laboratory work has identified genomic changes associated with the outcome of patients with lung cancer and the efficacy of targeted therapeutic agents. His research group was among those that discovered that patients with partial and complete responses to the epidermal growth factor receptor inhibitors gefitinib and erlotinib have mutations in the epidermal growth factor receptor and the technology has been licensed to Genzyme. Dr. Johnson leads a research team that continues to make genomic discovery and is instrumental in applying these findings to the clinical treatment of patients with lung cancer.

Dr. Johnson is a member of the External Scientific Committee for the NCI and NHGRI Pilot Project Characterizing Cancer Genomes. He served as Chair of the American Society of Clinical Oncology (ASCO) Communications Committee in 2005 and became Chair of the Education Committee in 2007. He recently was elected to serve as a member of the ASCO Board of Directors. He recently received the ASCO Cancer Foundation's Translational Research Professorship.